摘要
目的探讨原发性肝癌（PHC）患者血清中性粒细胞明胶酶相关脂质运载蛋白（NGAL）及基质金属蛋白酶9（MMP9）的变化及临床意义。方法采用酶联免疫吸附测定（ELISA）检测47例PHC患者（PHC组）及19例健康体检者健康血清中NGAL及MMP9水平,并分析二者与临床病理的联系,同时使用ROC曲线分析二者对PHC的诊断价值,Kaplan-Meier生存曲线分析不同NGAL、MMP9水平的生存差异。结果 PHC组NGAL、MMP9水平明显高于健康体检者对照组,差异有统计学意义（P〈0.05）;NGAL及MMP9的水平在Ⅲ~Ⅳ期组高于Ⅰ~Ⅱ期,差异有统计学意义（P〈0.05）;血清MMP9、NGAL检测灵敏度分别为70.2%和83.0%。二者联合检测可提高灵敏度至94.9%。Kaplan-Meier生存分析发现血清NGAL水平高患者预后差。结论 PHC患者血清NGAL及MMP9与PHC的发生、发展密切相关;联合检测血清水平NGAL及MMP9可明显提高敏感度,对PHC诊断及预后指标有一定的价值。
Objective To explore the changes of matrix metalloproteinase 9（MMP9） and neutrophil gelatinase associated li-pocalin（NGAL） in primary hepatic carcinoma and its clinical significance .Methods Enzyme-linked immunosorbent assay （ELISA） was used to detect the serum level of MMP9 and NGAL in 47 patients with primary hepatic carcinoma and 19 healthy controls .The association between serum MMP9 and NGAL levels with the clinicopathological features of hepatic carcinoma were evaluated .ROC curves were used to analyze the influence of MMP9 and NGAL on the diagnostic value .Kaplan-Meier method was used to evaluate the relationship between the expressions of NGAL and MM P9 and the prognosis of patients with HCC .Results Serum MMP9 and NGAL levels in hepatic carcinoma patients are significantly higher compared with normal controls （P ≤ 0 .05） .The serum level of MMP9 and NGAL in primary hepatic carcinoma was positively correlated with TNM stage （P≤ 0 .05） .The sensitivity and specifici-ty of MMP9 and NGAL for primary hepatic carcinoma were 70 .2% and 83 .0% .The sensitivity of the joint detection were 94 .9% . Kaplan Meier survival curves showed that cumulative survival rates of patients with positive expression of NGAL were significantly lower than those of patients with negative expression .Conclusion MM P9 and NGAL might play an important role in gastric cancer generation and development .Monitoring of serum MMP9 and NGAL levels might be helpful for diagnosis and evaluation of progno-sis for primary hepatic carcinoma .
出处
《重庆医学》
CAS
北大核心
2016年第17期2357-2359,共3页
Chongqing medicine
